Diagnostic Relevance of ADAMTS13 Activity: Evaluation of 28 Patients with Thrombotic Thrombocytopenic Purpura – Hemolytic Uremic Syndrome Clinical Diagnosis

Dragica Vučelić1, Danijela Miković2, Zoran Rajić3, Nebojša Savić4, Živko Budišin5, Nebojša M. Antonijević6,7, Slobodan Obradović8, Dragana Jevtić9, Roberta Palla10, Carla Valsecchi10, Flora Peyvandi10

1Clinic of Digestive Surgery, Clinical Center of Serbia, Belgrade, Serbia; 2Blood Transfusion Institute of Serbia, Belgrade, Serbia; 3Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia; 4Clinic of Vascular and Endovascular Surgery, Clinical Center of Serbia, Belgrade, Serbia; 5University Children’s Hospital, Belgrade, Serbia; 6Clinic of Cardiology, Clinical Center of Serbia, Belgrade, Serbia; 7School of Medicine, University of Belgrade, Belgrade, Serbia; 8Clinic of Emergency Internal Medicine, Military Medical Academy, Belgrade, Serbia; 9Mother and Child Health Care Institute of Serbia “Dr Vukan Cupić”, Belgrade, Serbia; 10U.O.S. Dipartimentale per la Diagnosi e la Terapia delle Coagulopatie, A. Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano and Luigi Villa Foundation, Milan, Italy

SUMMARY

Introduction The significance of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motif-13) activity for diagnosis and therapy of thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) is still a controversial issue.

Objective The aim of this report was to analyze the value of ADAMTS13 measurements in the diagnosis of TTP and HUS.

Methods At presentation, we analyzed patients with idiopathic TTP (n=18), secondary TTP (n=4), diarrhea positive HUS (n=3) and diarrhea negative HUS (n=3) treated in Belgrade, Serbia from 2004 to 2010. ADAMTS13 activity from acute phase samples was measured using the residual collagen binding activity assay at the Haemophilia and Thrombosis Centre, Milan, Italy.

Results There was a significant correlation between reduced ADAMTS13 activity and idiopathic TTP diagnosis (p=0.000) as well as between lower ADAMTS13 activities and higher reticulocytes (p=0.017) and lactate dehydrogenase levels (p=0.027). Significant correlation was also found between higher protease activity and diagnosis of HUS (p=0.000). There was a statistically significant correlation between higher ADAMTS13 activities and higher platelets count (p=0.002), blood urea nitrogen (p=0.000), and creatinine level (p=0.000).

Conclusion Severe ADAMTS13 deficiency points at the diagnosis of idiopathic TTP and it is present in the secondary TTP but not in HUS.

Keywords: thrombotic thrombocytopenic purpura; hemolytic uremic syndrome; ADAMTS13; diagnosis

INTRODUCTION

Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are manifestations of excessive microvascular platelet adhesion/aggregation, and present dangerous thrombotic microangiopathies (TMA) with dramatic clinical presentation and sometimes fatal outcome, even with rapid diagnosis and proper therapy. Most frequently involved organs are the brain, kidneys, heart, spleen, pancreas, and adrenals [1, 2, 3].

The pathophysiology of TTP appears to involve the largest of the unusually large von Willebrand factor (ULvWF) polymers. Upon expression by endothelial cells, vWF is secreted into the circulation as ULvWF. Normally, these multimers are processed into smaller regular sized multimers in the high-shear environment of the arterial circulation which will not spontaneously react with platelets [1, 4]. The vWF processing activity is now known to be a specific vWF-cleaving metalloprotease in normal plasma that prevents persistence in the circulation of ULvWF multimers [5, 6]. Specific vWF-cleaving metalloprotease is characterized as a 13th member of a large array of structurally related enzymes known as the ADAMTS (disintegrin and metalloprotease with thrombospondin type 1 repeats) family, and is denoted as ADAMTS13. In patients with TTP, processing of the ULvWF multimers is impaired due to the deficiency of the ADAMTS13. This eventually results in formation of the characteristic blood clots found in the microcirculation [1, 4].
There are several types of TTP [7, 8]. Congenital chronic relapsing TTP is associated with a severe constitutional deficiency of ADAMTS-13 due to inherited ADAMTS13 gene defects (2% to 3% of patients) [9, 10]. Chronic relapsing TTP usually manifests in childhood. If recognized early enough and treated successfully, it then recurs at approximately three-week intervals indefinitely. Recurrences are predictable enough that treatment with plasma infusion will prevent them [1, 7, 8].

A much more common are acquired forms of TTP. Pathophysiologically most acquired forms of TTP is related to autoantibodies against ADAMTS13 [1, 4, 5]. Acute idiopathic TTP is the most common type of TTP seen in clinical practice. Single episode TTP occurs without a known cause and has no recurrence (about two thirds of patients). In the remainder, the disease recurs at intermittent and unpredictable intervals (intermittent or relapsing TTP) [1, 8, 10]. Many patients with acquired idiopathic TTP have absent or severely reduced plasma ADAMTS13 activity during an initial episode as well as during later recurrences. In these patients, ADAMTS13 activity usually increases toward normal on recovery from a single or recurrent episode [1]. If an identifiable cause (infections, autoimmune conditions, lymphomas, cancer, chemotherapeutics, immunosuppressants, platelet aggregation inhibitors allogeneic hematopoietic stem cell transplantation, pregnancy) precipitates the illness it is classified as secondary [7, 8]. It has been considered that patients with secondary TTP almost never have severe ADAMTS13 deficiency [4].

TTP is one of the most difficult diagnoses for the clinical hematologist to make, due to the rarity of the disease and the poor specificity of clinical and laboratory signs and symptoms. The incidence of idiopathic TTP is estimated to be 4.5/1 million person/year, being higher in blacks [10, 11]. Severe thrombocytopenia and microangiopathic hemolytic anemia – MAHA (without an alternative cause) along with neurologic symptoms and signs due to predominantly ischemia or infarction of brain (in 50% to 71% of episodes), constitute the characteristic TTP clinical triad [1, 4]. Fever and/or renal dysfunction occur in a minority of these patients. Consumptive thrombocytopenia and MAHA, together with fragmented red cells in blood smear and elevated serum levels of lactate dehydrogenase, (LDH) provide the clinician with the most diagnostically useful laboratory signs [11].

In closely related HUS, ischemia is predominantly renal. HUS is clinically recognized by simultaneous occurrence of thrombocytopenia and MAHA along with acute renal failure [1, 12]. Approximately 50% of cases of acquired HUS appear after gastrointestinal infection caused by Shiga toxin producing Escherichia coli 0157:H7 (diarrhea associated hemolytic uremic syndrome – D+HUS or typical HUS or epidemic form) [4, 8]. HUS without antecedent diarrhea is referred to as “atypical HUS” (diarrhea negative hemolytic uremic syndrome – D-HUS or sporadic form). ADAMTS13 deficiency rarely if ever occurs in D+HUS. Patients with atypical HUS seldom have ADAMTS13 deficiency and frequently turn out to have abnormalities in the regulation of the alternate complement pathway due to mutations in complement factor H, factor I, factor B, or membrane cofactor protein [1, 4, 8].

Although traditionally considered separate entities, the distinction between TTP and HUS remains a matter of controversy because both syndromes often overlap [2]. Severe renal involvement in a patient with TTP or extrarenal manifestations in a patient with HUS can obfuscate clinical boundaries between the two syndromes [1].

TTP and HUS are clinical diagnosis [1]. As a practical matter, very few laboratories can perform ADAMTS13 assays rapidly enough, and the clinician must make a diagnosis and initiate therapy without this information. Three features of the classic pentad: renal involvement, neurologic symptoms, and fever are not necessary in establishing the diagnosis. Thus, the presence of thrombocytopenia and MAHA is sufficient for the diagnosis as not all other features are always present from the outset [4, 12, 13].

Although it has been proposed [14] that severe ADAMTS13 deficiency specifically defines TTP, the current prevailing opinion is that not all patients appropriately diagnosed with idiopathic TTP on the basis of clinical and laboratory symptoms and signs have severe protease activity [11]. On the other hand, total deficiencies of ADAMTS13 were observed in TTP forms secondary to other diseases or conditions [3]. In contrast to another largely accepted concept that patients with HUS have normal or moderately reduced ADAMTS13 activities, it has been demonstrated that reduced or undetectable levels of protease activity were present in plasma of some patients clinically diagnosed as having HUS [3, 15]. These provocative findings supported the views that these two syndromes should be identified clinically as TTP-HUS [2, 16].

It is well documented in TTP patients that early recognition and diagnosis as well as timely treatment with plasma exchange (PE) as the first-line therapy reduce mortality rate with long-term remission of 80-90%. The presence of antibodies of ADAMTS13 and the accumulation of ULvWF multimers in the patient’s plasma of acquired disease types suggest that the removal of such pathologic entities with PE would result in improvement of patients. The use of fresh frozen plasma (FFP) as the replacement fluid has the added benefit of infusing normal donor ADAMTS13. In patients without antibodies to the cleaving protease (congenital TTP), only 10 to 15 mL/kg of FFP infused every 2 to 3 weeks can achieve remission [1, 2, 7, 8, 12, 17, 18, 19]. Alternative therapeutic approaches, mainly based on immunosuppressive agents, have been used for resistant patients, but there is still no consensus as to the best approach [13]. Furthermore, some patients with HUS improved in association with PE. It is therefore appropriate to urgently commence daily PE procedures for all adult patients and older children with a clinical diagnosis of TTP or HUS [1].

**OBJECTIVE**

In 28 patients with TTP and HUS we evaluated the relationship between diagnostic laboratory parameters and
clinical diagnosis, the value of ADAMTS13 measurements in establishing the diagnosis of TTP and HUS, and correlation between ADAMTS13 activities and anti-ADAMTS13 autoantibodies with standard diagnostic parameters.

METHODS

Patients

In a 6-year period (between August 2004 and February 2010) 28 patients clinically diagnosed with TTP and HUS were admitted into three hospitals in Belgrade, Serbia: Clinic of Hematology - Clinical Centre of Serbia, Military Medical Academy, Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”. There were 22 female (78.6%) and 6 male (21.4%) patients included in this study. The median age was 39 years with a range of 17 to 68 years.

Clinical diagnosis

Clinical diagnosis was established based on the presence of MAHA (hemoglobin level below 120 g/L, elevated LDH, undetectable serum haptoglobin, evidence of erythrocytes fragmentation: at least 2 schistocytes per high-power field in peripheral blood smear, reticulocytosis, negative direct antiglobulin test), thrombocytopenia (platelet count less than 150×10⁹/L), presence/absence of fever, presence/absence of neurological signs and symptoms, and presence/absence of renal dysfunction/acute kidney injury (AKI) [20]. The measurements of laboratory parameters were performed according to the conventional methods using blood samples obtained on admittance. Table 1 presents the main patients clinical and laboratory characteristics at the time of diagnosis.

Idiopathic TTP was defined as TMA with predominantly neurologic involvement occurring in patients with no apparent preexisting disease. Secondary TTP was defined as TMA with predominantly neurologic abnormalities in the presence of known predisposing conditions/precipitants for disease onset: autoimmune disease, systemic disease, malignancy, bone marrow transplant. D+ HUS was defined as TMA with predominant clinical presentation of renal impairment/AKI associated with a prodromal diarrhea in patients with previously normal renal function. D- HUS in patients without prodromal diarrhea was defined as TMA with predominant clinical presentation of renal impairment/AKI in those with previously normal renal function [4, 21]. Diagnosis of AKI was made based on existing specific criteria introduced by the Acute Kidney Injury Network: rapid time course (less than 48 hours), reduction in kidney function defined with absolute increase in serum creatinine of ≥0.3 mg/dl (≥26.4 μmol/l) or percentage rise in serum creatinine of ≥50% respectively as well as reduction in urine output defined as <0.5 ml/kg/hr for more than 6 hours [22, 23]. In all patients with AKI diagnosis, renal function was previously normal. The diagnosis of the disease was made on clinical grounds without knowledge of the results of ADAMTS13 assays.

Clinical presentation was identified as idiopathic TTP in 18, secondary TTP in 4, D+HUS in 3, and D- HUS in 3 patients. Secondary TTP was associated with systemic autoimmune diseases (patients N° 19, 21, 22) and cancer (patient N° 20). Patient N° 19, 21, 22 were diagnosed with connective tissue systemic disease, syndrome sicca and systemic lupus erythematosus (SLE). One patient (patient N° 25) defined as having D+HUS was on tacrolimus regular intake due to allogenous stem cell transplantation 3 years ago. One patient (patient N° 27) with D-HUS exhibited onset of disease in the context of SLE.

ADAMTS13 activity measurement

Plasma samples were collected on admission. The ADAMTS13 activity was measured at the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre in Milan, Italy.

ADAMTS13 activity was assayed using collagen binding enzyme immunoassay. The source of VWF used as protease substrate was a purified VWF concentrate (Facon Willebrand Humain Tres Haute Purite) provided by Laboratoire Francois du Fractionnement et des Biotechnologies (Lille, France). The product, which lacks endogenous ADAMTS13 activity, was reconstituted to a VWF concentration of 100 U/mL, aliquoted and stored at -30°C. The concentrate was then thawed, diluted 1 in 33 with 5 M urea in 5 mM Tris-HCl, pH 8, and incubated for 10 min at room temperature. Subsequently, 50 µL of the dilution of the VWF source were added to 100 µL of serial dilutions (1/10, 1/20, 1/40) of test plasma as a source of ADAMTS13. Test plasmas were diluted in 5 mM Tris-HCl, pH 8 containing 12.5 mM BaCl2 and 1 mM Pefabloc SC (Roche, Mannheim, Germany). Values were expressed as percentages of pooled normal plasma. The most recent laboratory evaluation of assay reproducibility yielded an intra-assay coefficient of variation of 9% and an inter-assay coefficient of variation of 12%. The lower limit of sensitivity was 6% of protease levels in pooled normal plasma taken as the reference standard. The lower value of the reference interval (46%) was set at the 5th percentile of the distribution of the values obtained in 200 healthy individuals [24].

Anti-ADAMTS13 antibodies testing

Anti-ADAMTS13 antibodies were detected by western blot analysis, as previously reported [24].

In this study, ADAMTS13 activities were arbitrarily divided into four categories, similar to the practice of some others authors [16]. The categories were as follows: 1. less than 6% which is the detection limit of the assay (severe deficiency); 2. between 6% and 25% (moderate deficiency); 3. between 26% and 46% (mild deficiency); 4. greater than 46% (normal).
Table 1. Clinical features (N=28)

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Year of onset</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Clinical type</th>
<th>Episode</th>
<th>Platelets (×10^9/L)</th>
<th>Hb (g/L)</th>
<th>LDH (U/L)</th>
<th>Ret (%)</th>
<th>Creatinine (μmol/L)</th>
<th>BUN (mmol/L)</th>
<th>Neurological abnormalities</th>
<th>Fever</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2004</td>
<td>55</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>36</td>
<td>79</td>
<td>602</td>
<td>8.5</td>
<td>50</td>
<td>4.6</td>
<td>Headache, hemiparesis</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>2005</td>
<td>27</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>14</td>
<td>89</td>
<td>4559</td>
<td>5</td>
<td>136</td>
<td>12</td>
<td>Headache, giddiness</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>2005</td>
<td>27</td>
<td>M</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>20</td>
<td>93</td>
<td>1372</td>
<td>17</td>
<td>102</td>
<td>7.6</td>
<td>/</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>2005</td>
<td>45</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>50</td>
<td>93</td>
<td>634</td>
<td>15</td>
<td>83</td>
<td>4.1</td>
<td>Headache, dizziness</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>2007</td>
<td>45</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>28</td>
<td>92</td>
<td>2929</td>
<td>7</td>
<td>183</td>
<td>24</td>
<td>/</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>2007</td>
<td>33</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>31</td>
<td>85</td>
<td>2089</td>
<td>5</td>
<td>87</td>
<td>3</td>
<td>Headache, paresthesias</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>2007</td>
<td>51</td>
<td>M</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>16</td>
<td>65</td>
<td>1726</td>
<td>5</td>
<td>144</td>
<td>7</td>
<td>Headache</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>2008</td>
<td>39</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>5</td>
<td>73</td>
<td>1246</td>
<td>9</td>
<td>70</td>
<td>3.2</td>
<td>Headache, paresis n. facialis, paresthesias, aphasia, disorientation, hallucination</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>2008</td>
<td>25</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>23</td>
<td>65</td>
<td>3909</td>
<td>12</td>
<td>41</td>
<td>6</td>
<td>Headache, paresthesias</td>
<td>No</td>
</tr>
<tr>
<td>10</td>
<td>2009</td>
<td>21</td>
<td>M</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>5</td>
<td>117</td>
<td>1394</td>
<td>4.6</td>
<td>137</td>
<td>9</td>
<td>Headache, modified behavior, somnolence</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>2009</td>
<td>30</td>
<td>M</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>19</td>
<td>81</td>
<td>1319</td>
<td>12</td>
<td>91</td>
<td>7</td>
<td>/</td>
<td>No</td>
</tr>
<tr>
<td>12</td>
<td>2009</td>
<td>34</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>22</td>
<td>70</td>
<td>3347</td>
<td>14</td>
<td>61</td>
<td>5.1</td>
<td>Headache</td>
<td>Yes</td>
</tr>
<tr>
<td>13</td>
<td>2009</td>
<td>48</td>
<td>F</td>
<td>Idiopathic</td>
<td>First R after 7 years</td>
<td>19</td>
<td>73</td>
<td>2797</td>
<td>16.6</td>
<td>96</td>
<td>9.3</td>
<td>Seizures</td>
<td>No</td>
</tr>
<tr>
<td>14</td>
<td>2009</td>
<td>17</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>12</td>
<td>103</td>
<td>2795</td>
<td>9.3</td>
<td>67</td>
<td>10.1</td>
<td>Headache, apasia, coma</td>
<td>No</td>
</tr>
<tr>
<td>15</td>
<td>2009</td>
<td>41</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>28</td>
<td>72</td>
<td>1740</td>
<td>8.3</td>
<td>83</td>
<td>7.8</td>
<td>Dysphasia, headache, paresthesias, numbness</td>
<td>No</td>
</tr>
<tr>
<td>16</td>
<td>2009</td>
<td>33</td>
<td>F</td>
<td>Idiopathic</td>
<td>First R after 6 years</td>
<td>80</td>
<td>115</td>
<td>783</td>
<td>5.6</td>
<td>62</td>
<td>3.8</td>
<td>/</td>
<td>Yes</td>
</tr>
<tr>
<td>17</td>
<td>2009</td>
<td>66</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>3</td>
<td>86</td>
<td>4789</td>
<td>9</td>
<td>80</td>
<td>20.2</td>
<td>Stupor</td>
<td>Yes</td>
</tr>
<tr>
<td>18</td>
<td>2010</td>
<td>30</td>
<td>F</td>
<td>Idiopathic</td>
<td>Initial</td>
<td>11</td>
<td>78</td>
<td>3709</td>
<td>19</td>
<td>49</td>
<td>4.9</td>
<td>Headache, disorientation, hallucination, stupor</td>
<td>Yes</td>
</tr>
<tr>
<td>19</td>
<td>2004</td>
<td>23</td>
<td>F</td>
<td>Secondary</td>
<td>Initial</td>
<td>11</td>
<td>91</td>
<td>2750</td>
<td>17</td>
<td>107</td>
<td>29.9</td>
<td>Headache, sensorimotor polyneuropathy</td>
<td>No</td>
</tr>
<tr>
<td>20</td>
<td>2005</td>
<td>64</td>
<td>F</td>
<td>Secondary</td>
<td>Initial</td>
<td>41</td>
<td>56</td>
<td>1213</td>
<td>10</td>
<td>94</td>
<td>9.2</td>
<td>Seizures, stupor/coma</td>
<td>No</td>
</tr>
<tr>
<td>21</td>
<td>2007</td>
<td>68</td>
<td>F</td>
<td>Secondary</td>
<td>Initial</td>
<td>54</td>
<td>109</td>
<td>1187</td>
<td>4</td>
<td>104</td>
<td>15.9</td>
<td>/</td>
<td>Yes</td>
</tr>
<tr>
<td>22</td>
<td>2008</td>
<td>36</td>
<td>F</td>
<td>Secondary</td>
<td>Initial</td>
<td>10</td>
<td>52</td>
<td>4199</td>
<td>20</td>
<td>77</td>
<td>10.3</td>
<td>Slurred speech, bihemiparesis, paresthesias disorientation, somnolence</td>
<td>No</td>
</tr>
<tr>
<td>23</td>
<td>2005</td>
<td>52</td>
<td>F</td>
<td>D+HUS</td>
<td>Initial</td>
<td>95</td>
<td>96</td>
<td>925</td>
<td>2</td>
<td>813</td>
<td>45.6</td>
<td>/</td>
<td>Yes</td>
</tr>
<tr>
<td>24</td>
<td>2006</td>
<td>62</td>
<td>F</td>
<td>D+HUS</td>
<td>Initial</td>
<td>36</td>
<td>81</td>
<td>1551</td>
<td>6</td>
<td>429</td>
<td>43.8</td>
<td>/</td>
<td>Yes</td>
</tr>
<tr>
<td>25</td>
<td>2008</td>
<td>40</td>
<td>M</td>
<td>D+HUS</td>
<td>Initial</td>
<td>21</td>
<td>106</td>
<td>2057</td>
<td>10</td>
<td>378</td>
<td>33</td>
<td>/</td>
<td>No</td>
</tr>
<tr>
<td>26</td>
<td>2008</td>
<td>28</td>
<td>F</td>
<td>D-HUS</td>
<td>Initial</td>
<td>121</td>
<td>71</td>
<td>994</td>
<td>1</td>
<td>635</td>
<td>25.7</td>
<td>Headache, blurred vision</td>
<td>No</td>
</tr>
<tr>
<td>27</td>
<td>2008</td>
<td>20</td>
<td>F</td>
<td>D-HUS</td>
<td>Initial</td>
<td>47</td>
<td>86</td>
<td>1088</td>
<td>7</td>
<td>258</td>
<td>50.9</td>
<td>/</td>
<td>Yes</td>
</tr>
<tr>
<td>28</td>
<td>2008</td>
<td>32</td>
<td>M</td>
<td>D-HUS</td>
<td>Initial</td>
<td>101</td>
<td>98</td>
<td>790</td>
<td>3.7</td>
<td>1221</td>
<td>45</td>
<td>/</td>
<td>Yes</td>
</tr>
</tbody>
</table>

N – number of patients; F – female; M – male; R – relapse; Plt – platelets; Hb – hemoglobin; LDH – lactate dehydrogenase; Ret – reticulocytes; Cr – creatinine; BUN – blood urea nitrogen
Statistical analysis

Data were entered into a program SPSS for Windows version 18 and Statistica version 6.0. Variables were analyzed by using Chi-square test, Student t-test, Pearson’s correlation coefficient test, and Spearman’s rank correlation test. P values <0.05 and <0.01 were considered to be significant.

RESULTS

Clinical presentation

Among 28 acute episodes, 25/28 patients presented with their initial TTP or HUS episode, whereas 3/28 patients (cases N° 5, 13, 16) with idiopathic TTP experienced their first relapse after 11, 7, and 6 years from initial episode.

On diagnosis of 28 acute episodes, patients had multiple presenting symptoms and signs. Thrombocytopenia and MAHA were present in all patients. Of 18 idiopathic TTP acute episodes, heterogeneous neurological abnormalities were the paramount presenting symptoms occurring in 14 (77.7%) patients. The structure of central nervous system (CNS) abnormalities included headache, parestesia/paresis/numbness, disorientation/modified behavior, dysphasia/aphasia, hallucination, seizures, and stupor/coma. Headache was the most frequent symptom occurring in 12 patients (66.6%). Fever was present in 11 (61.1%) cases. Renal dysfunction, in the absence of AKI, presented with alterations of urinanalysis, such as micro-/macroscopic hematuria, proteinuria as well as moderately elevated blood urea nitrogen (BUN) and creatinine levels was manifested in 13 (72.2%) patients; some of them (2/13; 15.4%) experienced lumbal pain.

Among 4 patients with secondary TTP, CNS abnormalities (headache, slurred speech, disorientation, paresthesia, bitemporal ischesia, somnolence/stupor/coma) were present in 3 (75%), fever in 1 (25%), and mild renal impairment in 3 (75%) patients.

In the subgroup of 3 patients classified as having D+HUS, CNS abnormalities were absent in all of them while fever was present in 2 (66.6%) patients. AKI was manifested in 2 patients.

In the subgroup of 3 patients classified as having atypical HUS, all of them exhibited AKI. Headache and blurred vision were present in 1 patient. Also, one of them manifested fever.

Laboratory parameters

Laboratory parameters, median values, and standard deviations among the subgroups of patients classified as having idiopathic TTP (N=18), secondary TTP (N=4), D+HUS (N=3) and D- HUS (N=3) are listed in Table 2. Haptoglobin was undetectable in all patients (data not shown).

Relation of standard laboratory diagnostic parameters to TTP and HUS clinical type

The relationship between diagnostic laboratory parameters and the clinical diagnosis showed statistically significant differences (p<0.01) for the mean values of platelets, reticulocytes, BUN and creatinine. These results indicate that observed average values for platelets, BUN and creatinine were significantly higher (p<0.00001, p<0.00001, p<0.00001) whereas reticulocytosis was found to be significantly lower (p=0.007) among the patients clinically diagnosed with HUS compared to patients diagnosed with TTP.

Relationship between ADAMTS13 activity and TTP and HUS clinical diagnosis

ADAMTS13 activities being measured in samples collected from all patients on presentation are described in Table 3. The samples were tested in acute phase of the disease.

Severe ADAMTS13 deficiency was detected in patients with idiopathic (13/18) and secondary TTP (1/4). In the category of moderate protease deficiency there were 2/18 patients with idiopathic and 3/4 patients with secondary TTP. A mildly reduced ADAMTS13 activities were found in 3/18 patients with idiopathic TTP and 2/3 patients with D-HUS. Normal protease levels were measured only in the cases with HUS. In all patients with D+HUS protease levels were normal.

Thus, none of the patients with idiopathic and secondary TTP had normal and none of those with HUS had severe/moderate ADAMTS13 activity.

There was a significant correlation between reduced ADAMTS13 activities and idiopathic TTP clinical diagnosis (r=0.631; p<0.00001). A significant correlation was obtained in a relationship of higher protease activities with HUS clinical diagnosis (r=0.701; p<0.00001).

Table 2. Laboratory results on diagnosis (N=28)

<table>
<thead>
<tr>
<th>Laboratory tests</th>
<th>Clinical type</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Idiopathic TTP</td>
</tr>
<tr>
<td>Plt (x10⁹/L)</td>
<td>3-80 (23.3±18.4)</td>
</tr>
<tr>
<td>Hb (g/L)</td>
<td>65-117 (84.9±15.3)</td>
</tr>
<tr>
<td>Ret (%)</td>
<td>4-6-19 (10.1±4.6)</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>602-4789 (2316±1333)</td>
</tr>
<tr>
<td>Cr (µmol/L)</td>
<td>41-183 (90.1±37.9)</td>
</tr>
<tr>
<td>BUN (mmol/L)</td>
<td>3-24.3 (8.3±5.7)</td>
</tr>
</tbody>
</table>

TTP – thrombotic thrombocytopenic purpura; D+ HUS – diarrhea positive hemolytic uremic syndrome (HUS); D- HUS – diarrhea negative HUS
In acute episode there was a significant link (r=0.533; p=0.027). In terms of antibodies presence/absence, statistically significant correlations were obtained between antibodies presence and lower platelets number (r=0.491; p=0.008) as well as higher reticulocytes (r=0.485; p=0.009).

There was significant link between the absence of antibodies and higher BUN (r=0.666; p=0.00001) and creatinine (r=0.602; p=0.001) levels.

### DISCUSSION

In our patients, searching for statistical relationship between standard laboratory diagnostic parameters and TTP and HUS clinical diagnosis revealed differences across clinical type. There was a significant link between severity of renal function impairment i.e. clinical diagnosis with HUS and higher average values for platelets, BUN and creatinine as well as a relationship between higher reticulocytosis and TTP clinical diagnosis. These findings are in agreement with defining diagnostic features of TTP and HUS considering HUS description as a syndrome characterized by moderate thrombocytopenia (mean platelets number of 36x10^9/L) and hemolysis with predominant renal abnormalities, and TTP as a syndrome with severe thrombocytopenia and excessive hemolysis, respectively [8, 12, 21].

In this study, we found that decreased levels of ADAMTS13 were present in all patients (N=22) given diagnosis TTP, either primary or secondary forms. The prevalence of reduced ADAMTS13 activities was significantly higher in patients clinically diagnosed with idiopathic TTP. The great majority of the patients clinically diagnosed with idiopathic TTP (72.2%), had undetectable protease activity. On the whole, the results of protease activities in acute idiopathic TTP obtained in this small cohort are partially in concord with original findings [4, 5] but are in agreement with some others [24, 29, 35, 43]. Publications of Tsai and Lian [5] and Furlan et al. [6] independently found that the levels of plasma vWF cleaving protease were greatly reduced or absent during acute TTP episodes, with a return to a baseline values after recovery. They have detected autoantibody directed against the protease. The lock of cleaving protease was also determined in congenital TTP form, but in the absence of specific autoantibody. On the other hand, in patients with HUS, vWF cleaving protease activities were normal or only moderately reduced. Veyrader et al. [3] investigated multicenter prospective cohort of 111 patients (66 manifesting as TTP and 45 as HUS). They found normal ADAMTS13 level in some patients with idiopathic TTP and decreased protease level in some patients with HUS. Among patients with idiopathic TTP and decreased protease level, in around one third of them partial deficit was observed. In Vesely et al. [16] prospective study of 142 TTP-HUS patients, among 48 patients within the clinical category of idiopathic TTP, only 16 (33.3%) of them had severe protease deficiency.

### Table 3. ADAMTS13 functional activity in acute TTP and HUS episodes (N=28)

<table>
<thead>
<tr>
<th>Clinical type</th>
<th>ADAMTS13</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;6%</td>
<td>6–25%</td>
<td>26–46%</td>
<td>&gt;46%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idiopathic TTP</td>
<td>13 72.2</td>
<td>2 11.1</td>
<td>3 16.7</td>
<td>0 0 0 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary TTP</td>
<td>1 25.0</td>
<td>3 75.0</td>
<td>0 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D+HUS</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>3 100.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-HUS</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>2 66.7</td>
<td>1 33.3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 4. Anti-ADAMTS13 antibodies in the frame of clinical diagnosis and different categories of protease level (N=28)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Anti-ADAMTS13 antibodies</th>
<th>ADAMTS13</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;6%</td>
<td>6–25%</td>
<td>26–46%</td>
<td>&gt;46%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idiopathic TTP</td>
<td>Absent</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>13 72.2</td>
<td>2 11.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idiopathic TTP</td>
<td>Absent</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Present</td>
<td>1 25.0</td>
<td>1 25.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Relationship between anti-ADAMTS13 antibodies and TTP or HUS clinical diagnosis

Anti-ADAMTS13 antibodies were demonstrable in a total of 17/28 (60.7%) patients. The antibodies were identified among the patients that were categorized as having reduced protease activities. In the category of normal protease activity antibodies were not present (Table 4).

The antibodies were detected in 15/18 (83.3%) patients diagnosed with idiopathic TTP. In plasma of all patients (13/18; 72.2%) with idiopathic TTP and severe deficiency of ADAMTS13 antibodies were present. Among the remaining patients with idiopathic TTP, antibodies were present in 2/3 (11.1%) patients in category of mild protease activity. The patients with idiopathic TTP and moderate protease activity (2/18) had no demonstrable antibodies.

Among the patients with secondary TTP forms antibodies were detected in plasma of patient with SLE-sicca-related form with moderately reduced protease activity. Patients with underlying cancer and connective tissue systemic disease had no detectable antibodies.

In acute episode there was a significant link (r=0.533; p=0.003) of anti-ADAMTS13 antibodies presence with idiopathic TTP. Presence of antibodies was more frequent in idiopathic compared with other clinical forms. None of the patients with HUS had antibodies.

### Analysis of laboratory diagnostic parameters in relation to protease activities and antibodies presence

Statistically significant correlations were obtained between higher ADAMTS13 activities and greater platelets number (r=0.568; p=0.002), BUN (r=0.717; p=0.00001), and creatinine levels (r=0.701; p=0.00001). On the other hand, a significant correlations were demonstrated between lower ADAMTS13 activities and higher reticulocytes (r=0.448; p=0.017) and LDH levels (r=0.417; p=0.027).
Also, severe protease deficiency occurred among 2/10 women in immediate postpartum period of their first pregnancy. None of the patients with HUS and secondary drug associated TTP-HUS had severe protease deficiency. Peyvandi et al. [25] prospectively analyzed 100 patients with TTP. Nearly one third of the patients (28/100, 28%) had normal ADAMTS13 activities. Only approximately half of the patients (48/100, 48%) had very low levels (<10%) of ADAMTS13 activity. Moderately reduced protease levels were detected in 24/100 (24%) patients.

In our patients, severe ADAMTS13 deficiency was associated with the presence of specific antibodies in all patients suggesting the principal involvement of immune pathomechanism. Overall frequency of specific antibodies in our idiopathic TTP patients was 83.3% (15/18) with the presence of antibodies in all patients in severe ADAMTS13 deficiency category. Veyrader et al. [3] detected inhibitors in 31/65 (48%) patients with reduced ADAMTS13 activities. Inhibitors were observed only in patients with severe ADAMTS13 deficiency. In Vesely et al. [16] study, anti-ADAMTS13 antibodies were measured in 17/18 (94%) patients with severe protease deficiency. In Peyvandi et al. [25] study, in more than half of patients ADAMTS13 deficiency was not associated with the presence of inhibitors.

Of the remaining our patients, two had moderately and three mildly decreased ADAMTS13 activity associated with the presence of antibodies in two patients with mildly protease deficiency. The finding of antibodies in the plasma of patients with incomplete inactivated antigen is consistent with previous report that postulated incomplete inactivation of antigen as possible explanation for the partially reduced protease level with specific antibodies [25]. Severe ADAMTS13 activity secondary to the presence of antibodies was also found in one of our patients with secondary TTP and underlying SLE which is in correspondence with previous report [3]. Among the secondary forms partial protease deficiency without antibodies were demonstrated in two cases suggesting the influence of others possible mechanisms formerly proposed. These include: the presence of platelet aggregating factors, antibodies to platelets, antibodies to endothelial cells, endothelial injury, increased level of plasminogen activator inhibitor type 1 (PAI-1) and genetic factors [26-30].

Unlike TTP, in our patients normal ADAMTS13 values were predominant in patients diagnosed with HUS: in samples of all patients with D+HUS, and one patient with D-HUS (33.3%). Protease activities in the absence of antibodies were only slightly decreased in 2/3 (66.6%) patients with D-HUS. A significant correlation was obtained in a relationship of higher protease activities with HUS clinical diagnosis. The findings in our HUS patients are in accordance with generally accepted opinion relying on the majority of literature data [3, 5, 6, 16, 25].

Concerning the correlation between ADAMTS13 activity and laboratory characteristics we found significance referred to the correlation of higher ADAMTS13 activities and greater platelets number, BUN, and creatinine levels. Moderate thrombocytopenia as well as significant increment of BUN and creatinine values are criteria for HUS, and actually in this entity normal/mildly reduced activities of ADAMTS13 are registered in our study. In contrast, significant correlations were demonstrated between lower ADAMTS13 activities and higher reticulocytes and LDH levels. Severe thrombocytopenia/hemolysis with high elevation of LDH and substantial bone marrow response define TTP in our study. These findings indicate that in the majority of patients two syndromes may be discriminated based on either the values of laboratory parameters and ADAMTS13 activity.

**CONCLUSION**

In this study, we found that reduced ADAMTS13 activity characterizes both primary and secondary TTP with significantly high association of severe protease deficiency with idiopathic TTP. Conversely, normal ADAMTS13 activity points to the diagnosis of typical HUS but is not present in idiopathic and secondary TTP. Either normal or slightly reduced protease activity in the absence of specific antibodies defined atypical HUS. ADAMTS13 deficiency was associated with the severity of hemolysis and TTP clinical diagnosis with predominantly neurological abnormalities whereas patients diagnosed as HUS with normal/mildly reduced protease level manifested more impaired kidney function.

**REFERENCES**


Дијагностичка примењивост активности ADAMTS13: процена код 28 болесника са тромбозном тромбоцитопенијском пурпуром и хемолизно-уреумским синдромом

Драгица Вучелић1, Данијела Миковић2, Зоран Рајић3, Небојша Савић4, Живко Будишин5, Небојша М. Антонијевић6,7, Слободан Обрадовић8, Драгана Јевтић7,9, Роберта Пала10, Карла Валзеки10, Флора Пејванди10

1Клиника за дигестивну хирургију, Клинички центар Србије, Београд, Србија;
2Институт за трансфузију крви Србије, Београд, Србија;
3Клиника за хематологију, Клинички центар Србије, Београд, Србија;
4Клиника за васкуларну и ендоваскуларну хирургију, Клинички центар Србије, Београд, Србија;
5Универзитетска децна клиника, Београд, Србија;
6Клиника за кардиологију, Клинички центар Србије, Београд, Србија;
7Медицински факултет, Универзитет у Београду, Београд, Србија;
8Клиника за ургентну медицину, Војномедицинска академија, Београд, Србија;
9Институт за здравствену заштиту мајке и детета Србије „Др Вукан Чупић“, Београд, Србија;
10Одељење за дијагностику и лечење коагулопатија, Центар за хемофилију и тромбозу „А. Бјанки Бономи“, Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Универзитет у Милану и Фондација „Луки Вила“, Милано, Италија

Резултати Добијена је статистички значајна удрженошт између снижена активности ADAMTS13 и идиопатског ТТП (p=0,000), као и између снижена активности ADAMTS13 с једне стране и виших вредности броја ретикулопоцита (p=0,017) и лактат- декидрогеназе (p=0,027) с друге. Уочена је и значајна корелација између виших активности ADAMTS13 и дијагнозе ХУС (p=0,000). Статистички значајна корелација је забележена и између више активности ADAMTS13 с једне стране и виших вредности броја тромбоцита (p=0,002), уреје (p=0,000) и креатинина (p=0,000) с друге.

Закључак Недостатак ADAMTS13 тешког степена говори у прилог дијагнози идиопатског ТТП и налази се и у секундарном ТТП, али није одлика ХУС.

Кључне речи: тромбозна тромбоцитопенијска пурпур; хемолизно-уреумски синдром; ADAMTS13; дијагноза

Кратак садржај
Увод Значај дијагностичке специфичности активности ADAMTS13 (енгл. A Disintegrin And Metalloproteinase with ThromboSpondin motif-13) у тромбозном тромбоцитопенијском синдрому (ТТП) и хемолизно-уреумском синдрому (ХУС) и даље је предмет расправа.

Циљ рада Циљ истраживања је био да се испита значај активности ADAMTS13 у дијагнози акутног ТТП-ХУС.

Методе рада Испитани су болесници са идиопатским ТТП (18 испитаника), секундарним ТТП (4), дијаракт-позитивним (Д+) ХУС (3) и дијаракт-негативним (Д-) ХУС (3) који су лечени у Београду у периоду 2004–2010. године. Активност ADAMTS13 мерена је у акутној фази болести методом реци-дуалног колапен-везујућег имуноесеја у Центру за хемофилију и тромбозу у Милану.

Примљен • Received: 15/03/2012 Прихваћен • Accepted: 22/05/2013

Vučelić D. et al. Diagnostic Relevance of ADAMTS13 Activity: Evaluation of 28 Patients with TTP – HUS Clinical Diagnosis

doi: 10.2298/SARH1308466V